Logo

Abbott Receives FDA's Emergency Use Authorization for its Point-Of-Care Test to Detect Novel COVID-19 in Five Minutes

Share this

Abbott Receives FDA's Emergency Use Authorization for its Point-Of-Care Test to Detect Novel COVID-19 in Five Minutes

Shots:

  • Abbott has received the US FDA’s EUA for its molecular point-of-care test to detect novel COVID-19 and runs on its ID NOW platform- delivering positive results in just five mins. and negative results in 13 mins.
  • The ID NOW Covid-19 test allows HCPs to perform molecular POC testing outside the hospital in outbreak hotspots. The company anticipates scaling up manufacturing to deliver 50-000 tests/day with its expected launch in next week
  •  This marks Abbott’s second FDA’s EUA- following its first EUA for RealTime SARS-CoV-2 test- which runs on m2000 RealTime molecular system for centralized lab environments. Combining both the tests- Abbott expects to produce ~5M tests in April

Click here ­to­ read full press release/ article | Ref: Abbott | Image:  Abbott


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions